Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Common Equity (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Common Equity data on record, last reported at $663.2 million in Q3 2022.

  • For Q3 2022, Common Equity rose 14.06% year-over-year to $663.2 million; the TTM value through Sep 2022 reached $663.2 million, up 14.06%, while the annual FY2021 figure was $710.1 million, 29.62% up from the prior year.
  • Common Equity reached $663.2 million in Q3 2022 per AVIR's latest filing, roughly flat from $660.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $710.1 million in Q4 2021 and bottomed at -$76.5 million in Q3 2020.
  • Average Common Equity over 3 years is $439.5 million, with a median of $586.3 million recorded in 2021.
  • Peak YoY movement for Common Equity: skyrocketed 1198.48% in 2021, then grew 10.47% in 2022.
  • A 3-year view of Common Equity shows it stood at $547.8 million in 2020, then increased by 29.62% to $710.1 million in 2021, then dropped by 6.6% to $663.2 million in 2022.
  • Per Business Quant database, its latest 3 readings for Common Equity were $663.2 million in Q3 2022, $660.5 million in Q2 2022, and $679.9 million in Q1 2022.